48 results
8-K
EX-99.2
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
, but not limited to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals
8-K
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
: the goals, opportunity, and potential forreproxalap, ADX - 2191, ADX - 246, ADX - 248, and ADX - 629; anticipated clinical or regulatory milestones
8-K
EX-99.1
nf41cn3j
28 Mar 24
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
7:01am
8-K
EX-99.1
oo35gd 4a
13 Feb 24
Regulation FD Disclosure
4:00pm
8-K
EX-99.1
ntknf2qjzzeqlc9
4 Jan 24
Other Events
7:00am
8-K
EX-99.2
5efjlc
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
4v7e 09x6z2ma
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
lgj8l lwl4ac51x02
28 Nov 23
Regulation FD Disclosure
7:16am
8-K
EX-99.1
u2uce7cs3n8o
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.2
hjgsgdyqizn
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.2
3v7w0p25ymk5yvqb6ucx
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
wgrea28f 3bonig
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
3uv328qnvyyb5sm fg
15 Jun 23
Regulation FD Disclosure
7:01am